This page is an English translation of the Korean original. If there is any discrepancy, the Korean version prevails.
| Item | Details |
|---|---|
| A. Classification codes | ICD-10: G13.1 (C00-D48†) | Special Copayment Reduction: V287 (severe intractable disease, 5 years) |
| B. Synonyms | Paraneoplastic limbic encephalitis (PLE), paraneoplastic limbic encephalopathy, anti-NMDAR encephalitis-like syndrome |
| C. Adult onset | Likelihood of adult onset: very high - mainly arises in middle to old age (40s-70s) in association with an underlying malignancy (small cell lung cancer, testicular tumor, thymoma, etc.). Anti-NMDAR encephalitis is associated with ovarian teratoma in young women in their 20s-40s. |
| 1. History | 1960s: Corsellis's first description of limbic encephalitis → discovery of anti-Hu and anti-Ma2 antibodies → 2007: description of anti-NMDAR encephalitis → establishment of the autoimmune encephalitis classification system |
| 2. Causes | Small cell lung cancer, testicular tumor, thymoma, breast cancer, ovarian teratoma → antineuronal antibodies such as anti-Hu, anti-Ma2, anti-NMDAR, anti-LGI1, anti-CASPR2, and anti-AMPAR |
| 3. Genetics | Not directly hereditary; HLA class II background contributes to vulnerability to autoantibody formation; ectopic expression of neural antigens by the underlying tumor triggers the immune response |
| 4. General epidemiology | Overall incidence of autoimmune encephalitis about 1-2/100,000/year; anti-NMDAR encephalitis is the most common autoimmune encephalitis; paraneoplastic limbic encephalitis is a portion of the total |
| 5. Pathophysiology | Ectopic expression of tumor neural antigens → production of antineuronal autoantibodies → attack on limbic neurons in the hippocampus, amygdala, and frontal lobe → acute limbic dysfunction |
| 6. Symptoms | Subacute memory impairment (loss of short-term memory), behavioral and personality changes, psychiatric symptoms (anxiety, depression, psychosis), epileptic seizures, decreased consciousness, autonomic instability |
| 7. Signs | Increased hippocampal and amygdala signal on brain MRI T2/FLAIR; elevated cerebrospinal fluid protein and lymphocytosis; EEG abnormalities; positive antineuronal autoantibodies |
| 8. Screening | When subacute limbic encephalitis is suspected: antineuronal autoantibody panel (serum and CSF); search for malignancy (CT, PET-CT); EEG; brain MRI |
| 9. Diagnosis | Graus 2016 diagnostic criteria for autoimmune encephalitis; antibody testing (anti-NMDAR by CBA, anti-LGI1, anti-Hu, etc.); brain MRI; EEG; cerebrospinal fluid examination |
| 10. Treatment | First line: high-dose steroids, IVIG, plasma exchange; second line: rituximab, cyclophosphamide; treatment of the underlying tumor (resection of ovarian teratoma takes priority); antiepileptic drugs (seizure control) |
| 11. Prognosis | Anti-NMDAR encephalitis: about 75-80% functional recovery with early immunotherapy and tumor resection; intracellular antibodies such as anti-Hu have a poor prognosis; relapse rate about 12-20% |
| 12. Prevention | Early detection through regular screening for the underlying tumor; early antibody testing when new psychiatric or neurologic symptoms appear |
The concept of limbic encephalitis was established in the 1960s. In 1960, Brierley et al. first described a non-purulent encephalitis selectively involving the limbic system, and in 1968 Corsellis et al. reported three cases of limbic encephalitis associated with malignancy, establishing paraneoplastic limbic encephalitis as an independent clinical entity. Histopathology was described as characterized by inflammatory infiltration and neuronal loss in the limbic system, centered on the hippocampus and amygdala.
In the 1980s-90s, antineuronal autoantibodies were discovered. The anti-Hu (ANNA-1) antibody in 1985 and the anti-Ma2 (Ta) antibody in 1992 were identified, establishing the immune-mediated mechanism of paraneoplastic limbic encephalitis. These antibodies recognize intracellular antigens, and T-cell-mediated cytotoxicity is understood as the main mechanism of neural injury.
2007 was a revolutionary year in the history of autoimmune encephalitis. Dalmau et al. described anti-NMDAR encephalitis caused by anti-NMDA receptor (NMDAR) antibodies, showing that it occurs in association with ovarian teratoma in young women and is characterized by behavioral changes, seizures, decreased consciousness, and autonomic abnormalities. Anti-NMDAR encephalitis was quickly identified as the most common autoimmune encephalitis, and its good response to immunotherapy drew attention as a feature distinguishing it from antibodies against intracellular antigens.
Over the following decade, autoantibodies against cell surface or synaptic proteins, such as anti-LGI1, anti-CASPR2, anti-AMPAR, and anti-GABA-B, were discovered one after another, and the spectrum of autoimmune encephalitis expanded explosively. The 2016 publication of the diagnostic criteria for autoimmune encephalitis by Graus et al. standardized the clinical diagnostic system.
The cause of paraneoplastic limbic encephalopathy lies in an underlying malignancy. When tumor cells express proteins shared with limbic neurons, the autoimmune response against these proteins selectively attacks the limbic system.
Small cell lung cancer (SCLC): associated with anti-Hu (ANNA-1), anti-CV2, anti-amphiphysin, and anti-GABA-B antibodies. The most common causative tumor. Testicular germ cell tumor: specifically associated with anti-Ma2 (Ta) antibody. Arises in men aged 30-45. In anti-NMDAR encephalitis, associated with ovarian teratoma. Thymoma: associated with anti-CASPR2 and anti-LGI1 antibodies. Mainly arises together with neuromuscular junction disorder (Morvan syndrome). Breast cancer and endometrial cancer: associated with various antibodies.
Anti-Hu: multifocal nervous system involvement with sensory neuropathy and autonomic neuropathy. Anti-Ma2: mainly limbic encephalitis + brainstem encephalitis (oculomotor disorders). Anti-NMDAR: typical 5-stage clinical course (prodromal → psychiatric → unresponsive → hyperkinetic → gradual recovery). Anti-LGI1: characterized by short-term memory loss + faciobrachial dystonic seizures (FBDS). Anti-CASPR2: limbic encephalitis + neuromuscular hyperexcitability (myokymia, neuromyotonia) + autonomic abnormalities (Morvan syndrome).
Paraneoplastic limbic encephalopathy is not a directly hereditary disease. HLA class II genotype influences vulnerability to autoantibody formation. In anti-LGI1 encephalitis, the HLA-DRB1*07:01 allele is markedly overrepresented (odds ratio about 20-fold), confirming that the autoimmune response to this antigen is markedly increased on a specific HLA background. HLA associations have also been reported in anti-NMDAR encephalitis.
Genetic characteristics of the underlying tumor are also relevant. Ovarian teratoma contains neural tissue including NMDAR, which becomes a direct trigger of the autoimmune response. Neural tissue within the teratoma is exposed at an immunologically non-privileged site and induces autoantibodies against NMDAR.
The overall incidence of autoimmune encephalitis is estimated at about 1-2/100,000/year, similar to or higher than herpes simplex virus encephalitis. Recent studies have recognized that autoimmune encephalitis is much more common than previously thought. Anti-NMDAR encephalitis is the most common autoimmune encephalitis, accounting for about 30-40% of all autoimmune encephalitis. It occurs mainly in women under 30 (80% female), and ovarian teratoma accompanies it in about 30-50% of female patients. Anti-LGI1 encephalitis occurs mainly in men in their 60s-70s, with an association with malignancy in about 10%. Paraneoplastic limbic encephalitis (anti-Hu, anti-Ma2, etc.) occurs in middle to old age (50s-70s), and an association with malignancy is essential. In Korea as well, the frequency of diagnosis is increasing as awareness of autoimmune encephalitis grows, but accurate epidemiologic data are lacking.
The pathophysiology of limbic encephalopathy differs greatly depending on the antibody type.
Ectopic expression of neural proteins by tumor cells → antigen presentation by dendritic cells → CD8+ CTL activation → crossing the blood-brain barrier and direct destruction of hippocampal and amygdala neurons. Because the antibodies themselves have limited access to intracellular antigens, their direct pathologic role is small, and T-cell-mediated mechanisms are the main mechanism of injury. As a result, response to immunotherapy is limited.
Autoimmune IgG antibodies cross the blood-brain barrier and bind directly to receptors and channels on the surface of hippocampal and amygdala neurons. Anti-NMDAR antibody: induces internalization of NMDAR (NR1 subunit) → decreased receptor density → reduced NMDAR-mediated synaptic function → memory, behavioral, and consciousness disturbance. Anti-LGI1 antibody: dysfunction of the AMPAR-VGKC complex → synaptic hyperexcitability → epileptic seizures (especially FBDS). Because this mechanism is direct antibody-mediated neural dysfunction, it responds well to immunotherapy through antibody removal.
The clinical symptoms of limbic encephalopathy are characterized by selective involvement of the limbic system, including the hippocampus, amygdala, and frontal lobe.
Loss of short-term memory is the core symptom. Anterograde amnesia that progresses subacutely over days to weeks is characteristic. In the early stage of memory loss, bewilderment, anxiety, and agitation accompany it. As it worsens, past memories are also lost and the patient does not recognize people around them.
Personality changes (increased impulsivity, aggression), visual and auditory hallucinations, delusional thinking, anxiety and panic, and depression precede or accompany the cognitive symptoms. In anti-NMDAR encephalitis in particular, psychiatric symptoms are prominent and are often misdiagnosed as psychosis early on.
Various forms of epileptic seizures occur. Faciobrachial dystonic seizure (FBDS), the characteristic seizure of anti-LGI1 encephalitis, is a distinctive symptom in which brief (<3 seconds) motor seizures of the face and arm repeat dozens of times a day.
In anti-NMDAR encephalitis, autonomic instability (alternating tachycardia and bradycardia, blood pressure fluctuation, hypoventilation) is characteristic. Hyperkinetic dyskinesia (orofacial automatisms, upper-limb choreoathetosis) is also a feature of anti-NMDAR encephalitis.
On physical examination, decreased attention, disorientation, and memory loss are found, and on neurological examination primitive reflexes (grasp reflex, oral reflexes) may be positive. Brain MRI: increased signal in the hippocampal and amygdala areas on T2/FLAIR (FLAIR hyperintensity) is a characteristic finding of paraneoplastic limbic encephalitis. Hippocampal edema may be seen in the acute phase, and hippocampal atrophy is found in the chronic phase. With some antibodies (anti-NMDAR), initial MRI may be normal. Cerebrospinal fluid examination: elevated protein (50-100 mg/dL), lymphocytic pleocytosis (5-100 cells/μL), elevated IgG index, and increased intrathecal IgG synthesis are found. Specific oligoclonal bands may be detected. EEG: epileptiform activity (interictal epileptiform discharges, focal or generalized), predominant slow waves (delta, theta), and spike-wave complexes are found. The characteristic "extreme delta brush" pattern may be observed in anti-NMDAR encephalitis.
In patients with a combination of subacutely progressive memory impairment, behavioral change, epileptic seizures, and psychiatric symptoms, paraneoplastic limbic encephalopathy should be actively suspected and antibody testing performed. Immediate evaluation is needed especially for new-onset epilepsy, unexplained psychosis, or loss of short-term memory occurring within several weeks. Antineuronal autoantibody panel (serum + cerebrospinal fluid): extended panel testing including anti-Hu, anti-Ma2, anti-NMDAR, anti-LGI1, anti-CASPR2, anti-AMPAR, and anti-GABA-B. Because antibody detection sensitivity is higher in CSF than in serum in some cases (anti-NMDAR, etc.), testing both is recommended. Search for malignancy: CT of chest/abdomen/pelvis, ovarian ultrasound or MRI (women), testicular ultrasound (men), PET-CT (when CT is negative but antibodies are positive). Repeat tumor screening after 6 months may be needed.
The 2016 diagnostic criteria for autoimmune encephalitis by Graus et al. are the standard. Three criteria for diagnosing limbic encephalitis: ① one or more of subacute short-term memory loss, epileptic seizures, and psychiatric symptoms. ② Abnormal hippocampal signal on brain MRI T2/FLAIR. ③ CSF pleocytosis or EEG abnormality (temporal lobe epileptiform activity or slow waves). When 2 or more of these 3 are met and other causes are excluded, possible autoimmune limbic encephalitis is diagnosed. Confirmation of positive specific antibodies makes the diagnosis definite. For antibody testing, anti-NMDAR, anti-LGI1, etc. are confirmed by CBA (cell-based assay), and antibodies against intracellular antigens are confirmed by IIFA and line blot. Herpes simplex encephalitis, prion disease mimicking autoimmune encephalitis, Creutzfeldt-Jakob disease, and acute disseminated encephalomyelitis (ADEM) must be differentiated.
Treatment pursues two goals simultaneously: removal of the underlying tumor and immunosuppression.
When an ovarian teratoma is found, surgical resection (oophorectomy) is performed as soon as possible. In anti-NMDAR encephalitis, teratoma removal together with immunotherapy is a key factor in improving prognosis. For other tumors such as SCLC and testicular tumors, treatment is also started as soon as possible.
High-dose intravenous methylprednisolone (1 g/day × 5 days) + intravenous immunoglobulin (IVIG, 2 g/kg × 2-5 days) and/or plasma exchange (PE, 5-7 sessions) are given. These three are given simultaneously or sequentially.
If the response to first-line treatment is insufficient: rituximab (375 mg/m² once weekly × 4 doses or 1000 mg × 2 doses) or cyclophosphamide (750 mg/m²/month × 6 doses) is used. There is evidence that rituximab or cyclophosphamide improves prognosis in anti-NMDAR encephalitis. Long-term immunosuppression (mycophenolate mofetil, azathioprine) is considered to prevent relapse.
Prognosis varies greatly depending on the antibody type, whether the underlying tumor is treated, and the timing of diagnosis and treatment. In anti-NMDAR encephalitis, about 75-80% achieve functional recovery with early immunotherapy and tumor resection. However, about 30-40% follow a severe course requiring intensive care unit admission. The relapse rate is about 12-20%, and tumor recurrence is a risk factor for neurologic relapse. In anti-LGI1 encephalitis, memory function partially recovers in about 60-70% after immunotherapy. If FBDS persists, hippocampal atrophy and persistent memory impairment may remain. Paraneoplastic limbic encephalitis associated with intracellular antibodies (anti-Hu, anti-Ma2) has a poor prognosis, and neurologic impairment often progresses irreversibly even after treatment of the underlying tumor.
Primary prevention is not possible. Early detection of the underlying tumor: paraneoplastic limbic encephalopathy may be an early sign of a tumor, so tumor screening is performed immediately after the diagnosis of autoimmune encephalitis. Even if tumor-negative, repeat screening within 6 months is recommended. When anti-NMDAR encephalitis occurs in a young woman, actively search for ovarian teratoma and operate immediately if found. To avoid treatment delay from misdiagnosis as psychiatric symptoms or epilepsy, it is important to consider the possibility of autoimmune encephalitis early when acute psychiatric or neurologic symptoms appear.